Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2024-02-07 Investor Presentation
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PHN_FRANKFURT MIDCAP CONFERENCE 2024
Investor Presentation Classification · 1% confidence The document is titled "PHARMANUTRA 2030 FRANKFURT MIDCAP EVENT 2024" and contains extensive slides detailing the company's history, R&D focus, product markets, financial data (including revenue growth charts, though noting 2023 data is unaudited), and future strategy ("ROAD TO 2030"). This format, designed for presentation to investors and analysts during a specific event, strongly indicates an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). It is a comprehensive presentation package.
2024-02-07 English
PR - PHN PRELIMINARY REVENUES 2023
Earnings Release Classification · 1% confidence The document is a press release dated January 11, 2024, titled "PR - PHN PRELIMINARY REVENUES 2023". It announces the preliminary sales figures for the financial year 2023 for PharmaNutra S.p.A., detailing revenue growth and providing segment breakdowns. Although it contains detailed financial data, the text explicitly states that the figures are 'preliminary and not yet audited' and mentions that the 'full annual figures will be approved by the Board of Directors scheduled for 15 March 2024.' This structure—an initial, non-audited announcement of key financial results before the official filing—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the Interim Report (IR), nor is it a mere announcement of a report's publication (RPA), as it contains the actual preliminary results. FY 2023
2024-01-11 English
PHN - RICAVI PRELIMINARI 2023
Earnings Release Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata n. 20106-2) from PHARMANUTRA S.P.A. dated January 11, 2024. The subject (Oggetto) is "PHN - RICAVI PRELIMINARI 2023" (Preliminary Revenues 2023). The text explicitly states that the Board of Directors approved the preliminary sales data for the year 2023 and that these data are preliminary and not yet subject to auditing ("non sottoposti a revisione contabile"). It also mentions that the full annual data will be approved on March 15, 2024. This document provides the initial, high-level financial results for the period (2023 revenues) but is not the comprehensive, audited Annual Report (10-K) or the detailed Interim Report (IR). It fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it contains detailed tables, its primary function is the preliminary release of annual results. FY 2023
2024-01-11 Italian
PHN: Perdita qualifica PMI - Loss of SME status
Regulatory Filings Classification · 1% confidence The document is a formal announcement from PharmaNutra S.p.A. dated January 8, 2024, regarding the 'Perdita della qualifica di PMI' (Loss of SME status) because its market capitalization exceeded the threshold for three consecutive years. This type of announcement, which details a change in regulatory status affecting disclosure requirements (specifically referencing Consob Regulations and TUF articles regarding shareholding notifications), is a mandatory regulatory disclosure. Since it is not a full annual report (10-K), an earnings release (ER), or a specific capital change (CAP/SHA), but rather a general regulatory notification concerning compliance and status, it best fits the general 'Regulatory Filings' category (RNS) or potentially a specific notification if one were available. Given the options, RNS serves as the best fit for mandatory, non-standard regulatory updates that don't fall into the other specific categories like DIRS, DIV, or ER. The document structure is that of a press release/official notice, not a short announcement pointing to a separate report (which would be RPA).
2024-01-08 Italian
PR Financial Calendar 2024
Report Publication Announcement Classification · 1% confidence The document is a formal announcement from PHARMANUTRA S.P.A. titled "PR Financial Calendar 2024". It explicitly lists the dates for future Board of Directors meetings to approve financial results (Financial Statements, Interim Management Statements, Half-Yearly Report) and the subsequent Ordinary Shareholders' Meeting. This type of announcement, which informs the market about the schedule of future corporate events and report publications, fits best under the category of announcing the publication of reports. Since the document itself is not the full financial report (like 10-K or IR) but rather an announcement stating *when* those reports will be released, it aligns with the definition of Report Publication Announcement (RPA). The document length (5467 chars) is substantial enough that it's more than a simple RNS, but its core function is scheduling report releases.
2023-12-21 English
CS Calendario Finanziario 2024
Report Publication Announcement Classification · 1% confidence The document is a formal announcement from PHARMANUTRA S.P.A. dated December 21, 2023, titled 'CS Calendario Finanziario 2024' (Financial Calendar 2024). It explicitly lists the dates for upcoming corporate events, specifically the review and approval of financial results (Board meetings for quarterly/half-year reports and the AGM for annual report approval). The document itself is short (4904 characters) and serves to announce *when* other reports will be published, rather than being the report itself (like an ER or IR). This fits the definition of a Report Publication Announcement (RPA), which signals the release schedule of future financial documents. It is not a general regulatory filing (RNS) because it fits the more specific RPA category.
2023-12-21 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.